Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

GU Symposium 2021: Cabozantinib for Renal Cell Carcinoma With Brain Metastases

By: Julia Fiederlein
Posted: Friday, February 12, 2021

Cabozantinib seems to be safe and active in patients with brain metastases from renal cell carcinoma. Laure Hirsch, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues presented these findings during the virtual edition of the 2021 Genitourinary (GU) Cancers Symposium (Abstract 310).

“The high intracranial response rates seen in this retrospective analysis suggest cabozantinib has the potential for helping patients with difficult-to-treat brain lesions from kidney cancer,” commented study coauthor Toni K. Choueiri, MD, also of Dana-Farber, in a press release. “We look forward to building on these encouraging findings through the ongoing phase II CABRAMET trial led by our French colleagues, which is prospectively evaluating cabozantinib in patients with brain metastases from renal cell carcinoma.”

The investigators focused on 69 patients who were treated with cabozantinib monotherapy across 15 institutions in the United States, Belgium, Spain, and France. They were stratified by the radiologic presence (cohort 1; 36%) or absence (cohort 2; 64%) of progressing intracranial metastases. Follow-up data were provided for a median of 11 months.

The intracranial response rate was 61% in cohort 1, with three complete responses, and 57% in cohort 2. According to the investigators, 10% of patients had intracranial disease progression as the best response. In cohort 1, the extracranial response rate was 52%; the median durations of overall survival and time to treatment failure were 14.7 and 9.9 months, respectively. The extracranial response rate was 41% in cohort 2; the median duration of overall survival and time to treatment failure were 14.1 and 9.0 months, respectively.

As a result of disease progression and toxicities, 52% and 9% of patients discontinued treatment, respectively. Fatigue (77%) and diarrhea (46%) were the most commonly reported adverse events.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.